Newsroom
Featured News
- Business05 September 2022
Lotus Launches Lenalidomide Capsules 5mg, 10mg, 15mg, and 25mg, Generic Version of Revlimid® in the US
- Business21 September 2022
MITHRA AND LOTUS ANNOUNCE APPROVAL OF ALYSSA®, AN INNOVATIVE ORAL CONTRACEPTIVE, IN BOTH TAIWAN AND HONG KONG
- Investors08 September 2022
Monthly sales report for August 2022
- Business30 August 2022
Alvogen US, Lotus’s US Investment, Announces Favorable Ruling on Patents Related to the Company’s Proposed Generic to Xifaxan® for IBS-D
- Business25 August 2022
Lotus Receives Tentative Approval for Midostaurin ANDA from the US FDA
- Business22 August 2022
Lotus Crowned as One of Asia’s Best Employers of the Year 2022
- Business16 August 2022
Lotus and Fuji Pharma submitted 1st co-developed high value generic product in Japan
- Investors10 August 2022
Monthly sales report for July 2022
- Investors08 August 2022
Lotus hosts second quarter 2022 results investor conference
